The short answer on who qualifies

For most adults with MRI-confirmed cartilage damage in the knee, the answer is broadly yes. The ChondroFiller® injection pathway carries no upper age limit and no defect-size ceiling — making it relevant across a wide range from a single focal chondral lesion to more diffuse joint-surface wear.

The clearest positive indicators are:

• Cartilage damage confirmed on MRI, whether focal or diffuse
• Post-traumatic chondral lesions
• Osteochondritis dissecans (OCD)
• Cartilage damage arising after meniscal injury or ligament reconstruction, where the wider joint remains otherwise sound

There is no mandatory minimum defect grade in the current evidence, so patients at various stages of cartilage loss are assessed individually rather than screened out by a threshold alone.

Active patients in their 60s, 70s and beyond tend to be particularly well served by this pathway — especially those who have been advised that joint replacement may eventually be necessary but wish to pursue joint preservation first. The injection offers a meaningful intermediate step rather than an immediate move to theatre.

In practice, ChondroFiller® is delivered as an outpatient, ultrasound-guided injection under local anaesthesia. There is no surgical incision, no theatre admission, and no general anaesthetic. A thorough imaging-led assessment remains essential, as outcomes depend on the individual pattern of cartilage damage, surrounding tissue quality, and joint mechanics.

Joint mechanics that must be stable first

Before the scaffold can do its job, the joint environment needs to be mechanically sound. ChondroFiller® addresses the cartilage defect itself — not the biomechanical forces that may have contributed to it. Placing a regenerative scaffold into a joint where unresolved instability or malalignment continues to load the repair site reduces the chance of a durable result.

Three situations call for prior attention:

• Ligamentous instability — significant laxity, if untreated, creates shear forces across the repair area.
• Limb malalignment — a pronounced varus or valgus deformity concentrates load unevenly across the joint surface.
• A meniscal deficit driving the wear pattern — where a meniscal problem is the primary cause of accelerated cartilage loss, that underlying issue warrants assessment first.

The important clinical reality is that most patients presenting with an isolated focal chondral lesion and an otherwise intact joint already meet this prerequisite. For them, no additional procedure is required before the injection pathway is considered appropriate. The mechanical check is best understood as a clinical logic step — ensuring the conditions are right for repair — rather than as a reason to defer treatment.

Defect type and grade: what the MRI findings mean for candidacy

MRI reports use terminology that can feel opaque — phrases like "chondral lesion", "osteochondritis dissecans", or "Kellgren-Lawrence Grade IV changes" rarely arrive with a plain explanation of what they mean for treatment options.

Focal chondral lesions — areas of cartilage damage confined to one site — are the core indication for the ChondroFiller® injectable collagen scaffold. Delivered under ultrasound guidance, the scaffold gels in place at the lesion site and provides a structural matrix to support the body's own repair processes via acellular matrix-induced chondrogenesis.

Kellgren-Lawrence (KL) grading describes the overall degree of arthritic change visible on imaging, from Grade I (minor) to Grade IV (advanced joint-space narrowing). A common misconception is that reaching Grade III or IV closes the door on anything short of joint replacement. For the ChondroFiller® injection pathway, this is not the case — clinical evidence supports its use at KL Grade III–IV, which distinguishes it from surgical cartilage repair options that generally require a well-preserved surrounding joint environment.

Where MRI shows subchondral bone involvement (damage extending below the cartilage layer), or the lesion sits in a particular anatomical zone — for example, the trochlea versus the femoral condyle — these details act as outcome modifiers that a consultant weighs during assessment, rather than as blanket criteria for exclusion. Formal published thresholds based on lesion location or BMI are still maturing in the literature; individual imaging review is the appropriate basis for any accurate candidacy decision.

Why older active patients are often strong candidates

Being told that a knee replacement is 'the next step' does not mean it is the only step. For patients in that position — often still active, often in their 60s or 70s, and reluctant to accept major surgery without first exploring alternatives — the ChondroFiller® injection pathway offers a structured, evidence-supported route toward joint preservation.

The scaffold works through acellular matrix-induced chondrogenesis: placed under ultrasound guidance as an outpatient procedure, the collagen gel recruits the patient's own progenitor cells from the surrounding synovium and subchondral tissue, providing a structural framework in which those cells can mature and support the body's own repair processes. The biology is driven by the patient's own physiology — not by an implanted replacement material. That distinction matters: it means activity level and a desire to stay active are positive indicators for this pathway rather than concerns.

Clinical sources identify this cohort specifically as a valued pre-replacement group — patients who wish to maintain mobility, preserve their natural joint for as long as possible, and defer the recovery demands of arthroplasty. ChondroFiller® does not promise to halt disease progression in every case, and individual response depends on lesion characteristics and overall joint condition reviewed at consultation. It represents, however, a meaningful clinical step that sits between ongoing symptom management and major surgery — and one that does not close the door on joint replacement should it eventually be needed.

How ChondroFiller compares to microfracture and ACI

The comparison most patients eventually reach is worth setting out clearly: microfracture and ACI/MACI are established surgical pathways with a published track record, and understanding what that record actually shows makes it easier to weigh an injection-based alternative on its merits.

Microfracture works by drilling small channels into the subchondral bone to stimulate a healing response. The tissue it produces is fibrocartilage — mechanically inferior to native hyaline cartilage — and published data place its reliable upper limit at defects under 2–4 cm². Reoperation rates reach up to 41% in the literature.

ACI and MACI (autologous chondrocyte implantation) do generate hyaline-like tissue and can handle larger areas, but the process requires two separate surgical procedures, theatre admission, and general or spinal anaesthesia. Published series report reoperation rates up to 37% and complication rates as high as 17%.

ChondroFiller® is delivered as a single ultrasound-guided outpatient injection under local anaesthesia — no theatre, no staged procedure, no surgical recovery phase. In published series, the scaffold produces hyaline-like repair tissue across defects up to 6 cm², with a complication rate of approximately 0% and a reoperation rate of 3–8%. The injectable pathway extends that single-stage simplicity to patients with more diffuse wear who would not be candidates for a dry-field surgical approach.

These figures draw on published comparative data; which option best fits a particular defect, in a particular knee, depends on consultant review of imaging and individual clinical history.

What the outcomes data shows — and its honest limits

Across four independent study datasets, patients treated with the ChondroFiller® injectable scaffold show consistent knee function improvements of approximately 30 IKDC points — well above the minimum clinically important difference of 16.7 points used by researchers to define a meaningful patient benefit. The Jerosch et al. prospective post-market clinical follow-up study recorded a mean gain of 32.4 points, reaching an IKDC score of 80 at three-year follow-up, with benefit slightly increasing rather than declining over that period.

Structural repair matches the functional picture. MRI-assessed MOCART scores of 81–84 in European knee studies indicate more than 80% defect fill and good integration with surrounding native cartilage; in one cohort, the scaffold showed progressive maturation, with MOCART improving from 65.3 at four weeks to 81.6 at one year.

The safety record draws on more than 19,000 global cases, with a complaint rate of approximately 0.06%.

Two honest limits belong alongside those numbers. Durability data currently extend to three years; what happens beyond that horizon has not yet been established in the published literature. There are also no published blinded randomised controlled trials comparing the injection directly against a sham procedure or conventional surgery. Neither gap undermines the four-dataset consistency in functional and structural outcomes, but both are relevant to a patient weighing long-term expectations — and are best explored in a clinical assessment that reviews individual imaging, defect characteristics, and joint history.